Introduction
The management of prolonged seizures in the community is an important aspect in the care of children with severe epilepsy in view of the mortality and morbidity which can be associated with convulsive status epilepticus [1, 2] .
Children who have epilepsy and who have had prolonged seizures are the group usually prescribed rescue medication and in this study this was the case. Only children with epilepsy were included, not those with prolonged febrile seizures.
Rectal Diazepam, and more recently, intranasal and Buccal Midazolam are the rescue medications usually used in a community setting for prolonged convulsive seizures. A recent multicentre randomised control trial on the safety and efficacy of Buccal Midazolam versus Rectal Diazepam for the emergency treatment of seizures in children concluded that Buccal Midazolam Objectives: The objectives for this study were to determine the prevalence of use, safety and efficacy of different preparations of rescue medication used for prolonged seizures in children in the community and to use the information gained to inform good practice within the network. Methods: For all children in the EPIC area who had been prescribed epilepsy rescue medication for use in the community a questionnaire was completed by the clinician for each child relating to rescue medication prescribed, the epilepsy syndrome and seizure type. A questionnaire was also completed by the carers about their experience of the use of rescue medication in their child. Over 80% of the children had a community care plan in place. 90% of carers recalled receiving instruction/training in the administration of rescue medication. The majority (73%) of carers perceived Buccal Midazolam and Rectal Diazepam to be effective in preventing hospital admission. Conclusion: Buccal Midazolam in its propriety form is the rescue medication most commonly prescribed by EPIC epilepsy paediatricians. It was felt by families to be the safest (least side effects reported) and the most effective (most likely to terminate seizures) of the rescue medications. Children with severe epilepsy benefit from the use of rescue medications and the number of hospital admissions for prolonged seizures is reduced.
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was more effective than and as safe as Rectal Diazepam for children presenting to hospital with acute prolonged seizures [3] . In this study the intravenous preparation was used which poses practical problems for use in the community such as in school and respite care since there is a glass vial to open prior to administration.
In a previous randomised trial Buccal Midazolam was also found to be at least as effective as Rectal Diazepam in the acute treatment of seizures in a special residential centre for children with epilepsy, a setting with on site medical and nursing staff [4] . Both of the aforementioned studies provide useful information especially in a setting with medical and nursing staff present.
Two small studies have addressed the use of buccal and intranasal midazolam by parents in the community and found it to be preferred by parents and as efficacious as Rectal Diazepam [5, 6] . Again both studies used the intravenous preparation.
Seizures in the community do not always take place in the home with the parents present. The successful management of prolonged seizures in the community requires that the epilepsy paediatrician and specialist epilepsy nurse address other issues, in particular the support of school and respite care staff as well as the parent with regard to the use of rescue medication.
EPIC is a group of Paediatric Neurologists, lead secondary care paediatricians for epilepsy (hospital and community based) and paediatric epilepsy specialist nurses for Mersey region, North Wales, West Cheshire, Shrewsbury and more recently Swansea who meet regularly for the purposes of networking, education and developing shared good practice relating to paediatric epilepsy management.
The members of the EPIC group agreed that for reasons of personal dignity and social appropriateness for the child (especially teenagers) and ease of administration, especially for wheelchair users, that Buccal Midazolam is to be preferred for use of prolonged seizures in children in the community than the long standing practice of using Rectal Diazepam.
The use of glass vials as for the intravenous preparation in residential social services respite facilities and schools may be prohibitive and particularly on outings and so for practical reasons a number of paediatricians opted for the use of a proprietary ready to administer preparation despite the lack of clear evidence of its effectiveness in the literature. Anecdotally this preparation is felt to be effective but this study aims to address this and other questions relating to the use of rescue medication in a community setting in children within the geographical area covered by the EPIC group.
Methods

Children with epilepsy in the EPIC area (Mersey, North Wales,
West Cheshire, Swansea and part of Shropshire) who have been prescribed Buccal Midazolam or Rectal Diazepam for use at home, school and respite care were identified via lead epilepsy consultant and epilepsy nurse lists for all members of EPIC. 2. Questionnaires were completed by the Clinician (Paediatrician or Epilepsy Nurse) for each child relating to medication, the epilepsy syndrome, type of seizures, medication preparation prescribed and dose, and to enquire whether a care plan is in place for its community use. 3. Questionnaires were sent to parents to complete about their experience of use of rescue medication in their child. In some cases the paediatric epilepsy nurse administered the questionnaire to families at home or in the clinic situation.
Results
A total of 203 paediatrician questionnaires were administered and returned.
A total of 190 parent/carer questionnaires were returned from 203 sent out to parents well known to their paediatricians (which is probably the reason for the excellent response rate of 93%). For the 190 parent/carer questionnaires there was a paediatrician questionnaire for the corresponding child. The remaining 13 paediatrician questionnaires were not accompanied by a questionnaire completed by the child's carers.
Epilepsy syndromes and seizure types
According to the responses on the paediatrician questionnaire, over half of the children had symptomatic epilepsy (57%). Sixteen percent had idiopathic generalised epilepsies, 10% idiopathic focal epilepsies, 4% West syndrome, 2% Lennox Gastaut syndrome, 1 child had Landau-Kleffner syndrome and for 11% the epilepsy syndrome was not known or not stated.
A variety of seizure types were reported, the commonest type of seizure among the 379 reported being generalised clonic, tonic or tonic clonic (50%). Eighteen percent of the seizure types reported were absences (typical or atypical), 17% focal, 13% myoclonic, 2% atonic and no reflex seizures were reported.
Children in this study frequently had more than one seizure type with only around a third having only one seizure type (36%).
Forty-two percent of children had 2 seizure types, 17% had 3, 4% had 4 and 2% had 5 seizure types.
Types of rescue medication in use
The paediatricians reported that 51% of the children were currently receiving Buccal Midazolam as the sole rescue medication with 38% receiving Rectal Diazepam as the sole rescue medication. 3% were receiving nasal midazolam, 1% rectal paraldehyde and the remaining 7% were receiving combinations of these. In some areas there has been a delay in the changeover from diazepam to midazolam pending discussion with the local authority legal departments who need to agree to indemnify carers at school and respite facilities employed in Education and Social Services (personal communication with EPIC members).
Parents were asked about other medications prescribed in the past year and different from that currently being prescribed. Fiftysix of the 68 who answered responded that Rectal Diazepam had previously been used (82%). There has been a recent change in paediatrician prescribing from Rectal Diazepam to Buccal Midazolam.
The majority of current prescriptions (95%) were the proprietary buccal preparation rather than IV preparation at 1.1%. Ten milligrams was the dose most commonly prescribed (54%). 13% of prescriptions were for 7.5 mg, 16% were for 5 mg and 3% were for 2.5 mg. A variety of other doses (between 0.2 mg and 12.5 mg) were prescribed in 4% of children and 10% did not state the dose prescribed.
For those children receiving Rectal Diazepam 56% were receiving a dose of 5 mg and 25% a dose of 10 mg. When calculated on a weight basis the doses of Rectal Diazepam varied widely above and below the recommended 0.5 mg/(kg dose) À1 .
Care plans for administration of rescue medication in the community
89% of paediatricians and 79% of parents/carers reported that a rescue medication care plan was in place for rescue medication use in the community (home, school and respite care). Of those care plans in place (n = 151) 89% of parents reported that the care plans were in date (had been prepared or updated within the past year) Care plans are of course essential for schools and respite facilities many of whom will not administer the medication without a valid care plan in place. This is particularly the case for residential placements.
89% (of 190) parents/carers recalled receiving instruction/ training in the administration of rescue medication. They reported that training was received from a variety of sources, predominately nursing staff (53% from an epilepsy specialist nurse, 27% from a paediatric ward nurse and 10% from a community or school nurse).
Test doses of rescue medication
38% of families reported that rescue medication had either not been administered in the emergency situation prior to its prescription (29%) or they could not remember (9%) and these families were asked whether a test dose had been administered on the ward. Whilst only 12% recalled a test dose of diazepam, 61% recalled a test dose of midazolam.
For paraldehyde, none of the 4 children whose parents answered this question reported that a test dose had been given.
The much higher level of test doses for Buccal Midazolam may be related to its more recent introduction and hence perhaps better recall, or possibly the lack of clear objective evidence as to whether a test dose is needed.
Use of rescue medication in the community
Following prescription of rescue medication 75% of the families reported that they had needed to use it, 21% had not and 4% could not recall this. Whilst 41% reported that it had been administered 1-3 times in the previous year, 16% reported that they had used it 4-6 times, 9% had used it 7-9 times and 19% reported that rescue medication had been administered 10 or more times.
How well does rescue medication work
Thirty-six percent of families reported that Rectal Diazepam ''always worked'' in stopping seizures. 43% that it ''usually worked'', 15% that it ''rarely worked'' and 6% that it never worked. The corresponding responses for Buccal Midazolam were 55% ''always'', 31% ''usually'', 7% ''rarely'' and 7% ''never''. The families of the 9 children for whom paraldehyde had been used responded that it ''always worked'' in 4 cases, ''usually'' in 1 case, ''rarely'' in 2 cases and ''never worked'' in 2 cases.
Side effects of rescue medication
Parents/carers were asked whether side effects which cause them concern had occurred and 16% reported that they had. They were asked to give a brief description of the side effects of concern.
Thirteen were reported with Rectal Diazepam, 4 with Buccal Midazolam, 6 when combinations of rescue medications were used. The commonest side effect reported was drowsiness followed by respiratory difficulties, seven cases of respiratory depression were reported with diazepam and one with midazolam (''choking'') and 2 with a combination of Rectal Diazepam and Buccal Midazolam.
Does rescue medication prevent hospital admission
Thirty percent of the 142 parents responding to this question reported that hospital admission was ''always'' averted when rescue medication was used in the community for prolonged seizures, 43% that it was ''usually'', 10% ''rarely'' and 11% ''never''.
Discussion
Evidence for the use of rescue medication for prolonged epileptic seizures in hospital and residential specialist settings has been gathered [3, 4] but to date only small studies have looked at its usefulness in a community setting [5, 6] .
The study reported here looked at the current clinical practice within a paediatric epilepsy network and the views of the families using the rescue medication were sought as described.
Studies looking at community settings need to take into account rescue medication use in schools and social services respite facilities which, of course, requires not only parental acceptance but also clear explanation to local authorities including, for example, the lack of a product licence for Buccal Midazolam.
For paediatricians working in a community setting it is very clear that if rescue medication is to be used by families, schools and in respite care settings then the preparation must be practically easy to administer, careful written instructions (care plans) and training must be given (as well as advice whenever needed). This aspect of care seems to be well addressed by the EPIC network clinicians.
The children prescribed rescue medication have severe, predominately symptomatic epilepsy with a variety of seizure types. Of the 379 seizure types recorded on the questionnaire responses half were tonic clonic or tonic clonic seizures which are dramatic and easily recognisable, for the carer who can usually identify the beginning and end of the seizure, time it and be clear about when to administer rescue medication.
The paediatricians reported on current prescriptions, the parents were also asked about other rescue medications used in the previous year and for community use there has been a shift from Rectal Diazepam to Buccal Midazolam which is mainly used in its proprietary form rather than the intravenous preparation being used by the buccal route.
The doses of Rectal Diazepam prescribed varied enormously when calculated according to weight. The doses of proprietary Buccal Midazolam were more standardised at 2.5 mg, 5 mg, 7.5 mg and 10 mg for specific ages as recommended by the manufacturer. The occasional prescription of a dose outside this recommendation can be clearly explained in the care plan. This emphasises the importance of clarity and ease of administration in emergency situations in the community.
The issue of whether or not to give test doses for Buccal Midazolam has been clarified a little in that reported side effects were uncommon and no parent reported respiratory arrest requiring resuscitation or hospitalisation. However the questionnaire did not specifically ask this and perhaps should have in retrospect so that clearer guidance could have been given.
Three quarters of the children prescribed rescue medication for community use had required at least one dose in the previous year with almost a fifth having required more than 10 doses. These children clearly had epilepsy which was not controlled by their regular antiepileptic drugs and this is not surprising in view of the high prevalence of severe epilepsy syndromes in this group. It is encouraging that the majority of the children in this study avoid hospital admissions by the use of rescue medication for prolonged seizures and do not seem to suffer excessive adverse effects of concern to their carers. Although hospital admissions have been reduced it is clear that dialogue also needs to take place with the ambulance services who are involved in the transfer of children with status epilepticus to hospital. This is to be addressed at an EPIC network meeting.
Conclusions
Buccal Midazolam in its proprietary from is the rescue medication most commonly prescribed by epilepsy paediatricians in the EPIC network.
Almost two thirds of children who have not received benzodiapine rescue medication previously are given a test dose of Buccal Midazolam. This practice should be considered in the light of the small number of reported significant side effects with Buccal Midazolam.
Of the rescue medications in use Buccal Midazolam was felt to be the safest (least side effects reported) and the most effective (most likely to terminate seizures).
Children with severe epilepsy and their families benefit from the use of rescue medication in that the number of hospital admissions for prolonged seizures is reduced.
